Network meta-analysis finds medium-dose vitamin A superior to high-dose for pediatric pneumonia.
This is a network meta-analysis of randomized controlled trials evaluating different doses of vitamin A supplementation for children with pneumonia. The analysis synthesized evidence from a total sample of 3116 children, comparing low, medium, and high-dose regimens.
The authors found that medium-dose vitamin A supplementation was most effective for reducing the duration of fever and the duration of cough. For overall clinical outcomes, low-to-medium doses were consistently associated with better results than high-dose regimens. No pooled effect sizes, absolute numbers, or p-values were reported for these findings.
Key limitations noted by the authors include high heterogeneity among the included trials, the use of indirect comparisons between dose groups, and poor reporting of adverse events. Safety evidence was limited and inconclusive, with no serious adverse events reported.
The practice relevance is that low-to-medium dose vitamin A supplementation appears superior to high-dose regimens for alleviating clinical symptoms in children with pneumonia. However, the certainty of this evidence is limited, and the findings should not be interpreted as direct causal evidence due to the network meta-analysis design.